Structured Summary:
In adults with obesity, danuglipron significantly reduced body weight compared to placebo, though it was associated with higher rates of discontinuation due to adverse events.
| PICO | Description |
|---|---|
| Population | Adults with obesity. |
| Intervention | Danuglipron (PF-06882961), administered over 26 or 32 weeks in a dose-ranging study. |
| Comparison | Placebo over the same treatment duration. |
| Outcome | Danuglipron showed statistically significant reductions in body weight compared to placebo, with clinical significance noted. However, adverse events led to higher-than-expected discontinuation rates across all treatment groups, including placebo. |
Source: Buckeridge, Clare, et al. “Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.” PubMed. Read article here.
